Published on 9 May 2024 on Simply Wall St. via Yahoo Finance
ADC Therapeutics SA (NYSE:ADCT) First-Quarter Results: Here's What Analysts Are Forecasting For This...
Last week, you might have seen that ADC Therapeutics SA (NYSE:ADCT) released its quarterly result to the market. The early response was not positive, with shares down 6.8% to US$4.41 in the past week. The results overall were pretty much dead in line with analyst forecasts; revenues were US$18m and statutory losses were US$0.56 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Check out our latest analysis for ADC Therapeutics
